Osteoimmunologie: Wie die Entzündung den Knochenstoffwechsel beeinflusst

Zusammenfassung

Der Knochenumbau zeichnet sich durch ein ausgeglichenes Verhältnis zwischen Knochenresorption und Knochenaufbau aus. Auf zellulärer Ebene sind die Osteoblasten für den Knochenaufbau und die Osteoklasten für den Knochenabbau verantwortlich. Über ein fein abgestimmtes Zusammenspiel von molekularen Mechanismen, Zytokinen, Hormonen und Wachstumsfaktoren wird dabei die Knochenhomöostase gewährleistet. Das RANK/RANKL/OPG-System ist aktiv an der Reifung von Osteoklasten mit konsekutiv erhöhtem Knochenabbau beteiligt. Störungen der Knochenhomöostase können bei erhöhtem Abbau mit entzündlich-destruktiven Manifestationen und/oder einer Osteoporose einhergehen, hingegen bei erhöhtem Anbau eine Osteopetrose induzieren. Die vorliegende Übersichtsarbeit fokussiert auf die bekannten molekularen Mechanismen und pathophysiologischen Stoffwechselwege dieser Remodellingprozesse, insbesondere unter dem Einfluss von Entzündungsmediatoren, und stellt auch die Verbindung von Forschung zur Klinik dar.

Abstract

Bone remodelling is characterized by a balance between bone resorption and bone formation. The osteoblasts are responsible for bone synthesis and the osteoclasts for bone resorption. A finely adjusted interaction between molecular mechanisms leads, via cytokines, hormones and growth factors, to a homeostasis of the bone metabolism. Here, the RANK/RANKL/OPG-system is actively involved in the differentiation and function of osteoclasts and seems to play a central role in most pathophysiological mechanisms. An increased osteoclast activity results in inflammatory destructive manifestations and/or osteoporosis whereas an increased osteoblast activity can result in osteopetrosis. The present overview describes the known pathophysiological relevant metabolic pathways in this remodelling process especially the effect of inflammation on bone metabolism, and presents the links from bench to bedside.

Schlüsselwörter

Knochenstoffwechsel - Remodelling - Osteoporose - RANK/RANKL/OPG

Keywords

bone metabolism - remodelling - osteoporosis - RANK/RANKL/OPG

• Literatur

• 1 Allali F, Breban M, Porcher R et al. Increase in bone mineral density of patients with spondylarthropathy treated with anti-tumour necrosis factor (. Ann Rheum Dis 2003; 62: 347-349
• 2 Catrina AI, af Klint E, Ernestam S et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 2006; 54: 76-81
• 3 Charatcharoenwitthaya N, Khosla S, Atkinson EJ et al. Effect of blockade of TNF-alpha and Interleukin-1 action on bone resorption in early postmenopausal women. J Bone Min Res 2007; 22: 724-729
• 4 Cohen Jr MM. The new bone biology: pathologic, molecular, and clinical correlates. Am J Med Gent A 2006; 140: 2646-2706
• 5 Cohen SB, Dore RK, Lane NE et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299-1309
• 6 Dischereit G, Tarner IH, Müller-Ladner U et al. Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study. Clin Rheumatol 2013; 32: 377-381
• 7 Dore RK, Cohen SB, Lane NE et al. Effects of Denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent Glucocorticoids or bisphosphonates. Ann Rheum Dis 2010; 69: 872-875
• 8 Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-1450
• 9 Genovese MC, Van Den BF, Roberson SA et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010; 62: 929-939
• 10 Genovese MC, Durez P, Richards HB et al. One year efficacy and safety results of a phase II trial of secukinumab in patients with rheumatoid arthritis. Arthritis Rheum 2011; 63 (Suppl. 10) 147-148
• 11 Goldring SR. Inflammatory mediators as essential elements in bone remodeling. Calcif Tissue Int 2003; 73: 97-100
• 12 Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci 2006; 102: 385-396
• 13 Harre U, Georgess D, Bang H et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012; 122: 1791-1802
• 14 Hofbauer L, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490-495
• 15 Hofbauer LC. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). Ann Endocrinol (Paris) 2006; 67: 139-141
• 16 Kensuke K, Amano K, Yamada S et al. Tocilizumab monotherapy improves bone mineral density as well as TNF blockers plus methotrexate with methotrexate-resistant active rheumatoid arthritis. An Open-lable randomized clinical trial. T-bone Trial. Arthritis Rheum 2011; 63 (Suppl. 10) 147-148
• 17 Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-1411
• 18 Kim HR, Kim HY, Lee SH. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology 2006; 45: 1197-1200
• 19 Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005; 5: 618-625
• 20 Kotake S, Udagawa N, Takahashi N et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345-1352
• 21 Kremer JM, Fleischmann RM, Brzezicki J, Woodworth T, Fisheleva E, Alecock E et al. Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate: The LITHE Study. ACR program book supplement; 59. 2008
• 22 Lam J, Takeshita S, Barker JE et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481-1488
• 23 Lange U, Teichmann J, Müller-Ladner U et al. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-( antibody: a prospective open-label pilot study. Rheumatol 2005; 44: 1546-1158
• 24 Lange U, Müller-Ladner U. Glukokortikoid-induzierte Osteoporose. Z Rheumatol 2007; 66: 129-138
• 25 Lange U, Neumann N, Kürten B et al. The Impact of Serial Low-Dose Radon and Hyperthermia Exposure in a Therapeutic Adit on Pivotal Cytokines of Bone Metabolism in Ankylosing Spondylitis. Phys Med Rehab Kuror 2012; 22: 203-206
• 26 Lange U, Wettich T, Schneider C et al. Wirkung einer IL-6R-Inhibition bei Patienten mit rheumatoider Arthritis auf den Knorpel- und Knochenmetabolismus sowie die Knochendichte. Osteologie 2013; (Suppl. 01) S30, P25
• 27 Li P, Schwarz EM, O`Keefe RJ et al. RANK signalling is not required for TNF-alpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNF-alpha-mediated inflammatory arthritis. J Bone Miner Res 2004; 19: 207-213
• 28 Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. N Engl J Med 2000; 343: 1594-1602
• 29 Liu XH, Kirschenbaum A, Yao S et al. Interactive effect of interleukin-6 and prostaglandine E2 on osteoclastogenesis via OPG/RANKL/RANK system. Ann N Y Acad Sci 2006; 1068: 225-233
• 30 Lubberts E, Koenders MI, Oppers-Walgreen B et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004; 50: 650-659
• 31 Lubberts E, Koenders MI, van den Berg WB. The role of T-Cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005; 7: 29-37
• 32 Luo XH, Guo LJ, Xie H et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 2006; 21: 1648-1656
• 33 Meier FM, Frommer KW, Peters MA et al. Visfatin/pre-B cell colony-enhancing factor (PBEF): a proinflammatory and cell motility-changing factor in rheumatoid arthritis. J Biol Chem 2012; 287: 28378-28385
• 34 Moder A, Hufnagel C, Lind-Albrecht G et al. Effect ofcombined Low-Dose Radon- and HyperthermieTreatment (LDRnHT) of patients with ankylosing spondylitis on serum levels of cytokines and bone metabolism markers: a pilot study. Int J Low Radiation 2012; 7: 423-35
• 35 Moschen AR, Geiger S, Gerner R et al. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat Res 2010; 690: 95-101
• 36 Müller-Ladner U, Neumann E. Rheumatoid arthritis: the multifaceted role of adiponectin in inflammatory joint disease. Nat Rev Rheumatol 2009; 5: 659-660
• 37 Neumann E, Gay S, Müller-Ladner U. The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum 2005; 52: 2960-2967
• 38 Neumann E, Schett G. Knochenstoffwechsel. Z Rheumatol 2007; 66: 286-289
• 39 Neumann E, Frommer KW, Vasile M et al. Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases?. Arthritis Rheum 2011; 63: 1159-1169
• 40 Ritchlin CT, Haas-Smith SA, Li P et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111: 821-831
• 41 Sato K, Suematsu A, Okamoto K et al. Th 17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 2673-2682
• 42 Schett G, Kiechl S, Weger S et al. High-sensitive C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006; 166: 2495-2501
• 43 Smolen JS, Han C, van der Heijde DM et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009; 68: 823-827
• 44 Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibit progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2012; 71: 687-893
• 45 Takayanagi H, Ogasawara K, Hida S et al. T-cell- mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000; 408: 600-605
• 46 Thommesen L, Stunes AK, Monjo M et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem 2006; 99: 824-834
• 47 Vis M, Havaardsholm EA, Haugeberg G et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and RANKL serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1495-1499
• 48 Wong PK, Quinn JM, Sims NA et al. Interleukin-6 modulates production of T lymphocytes-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 2006; 54: 158-168
• 49 Xie H, Tang SY, Luo XH et al. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 2007; 80: 201-210
• 50 Yamaguchi N, Kukita T, Li YJ et al. Adiponectin inhibits induction of TNF-alpha/RANKL-stimulated NFATc1 via the AMPK signaling. FEBS Lett 2008; 582: 451-456